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Introduction
A photochemical treatment (PCT) process utilizing the psoralen (S-59) and long wavelength ultraviolet light (UVA, 320-400 nm) has been developed for treatment of platelet concentrates [1, 2] . PCT with S-59 and UVA is a nucleic-acid-specific inactivation process with a broad spectrum of activity against bacteria, viruses and leukocytes. S-59 reversibly intercalates into helical regions of DNA and RNA. Upon illumination with UVA, S-59 reacts with pyrimidine bases to form covalent monoadducts and cross-links with nucleic acids. Bacteria, viruses or cells with genomes which have been modified by
Materials and Methods

Disposables -Wet Components
The platelet additive solutions and the S-59 solution were provided in PL 2411 containers with tubing (a non-PVC plastic material made without a plasticizer; Baxter Healthcare Corporation, La Châtre, France). They were added to buffy coat platelets using a sterile connection device. 
Disposables -Dry Components
Whole blood was collected by using the Optipac ® Triple bi-filled kit (Baxter Healthcare). The kit consists of a primary 'bottom and top' container filled with 70 ml of CPD anti-coagulant solution, a secondary conventional container filled with 110 ml of SAG-M solution and an empty transfer container. Packs are made of PL 2209 plastic (a polyvinyl chloride (PVC) with a non-DEHP plasticizer). A 600-ml transfer pack with 8 leads was used to pool buffy coats (Baxter Healthcare). The Optidock buffy coat leukodepletion set consists of a Pall Autostop ® buffy coat filter, specifically designed to remove leukocytes in the production of platelets from buffy coats, and a 1.3-litre PL 2410 plastic container. The platelet illumination container was a 1-litre PL 2410 plastic container (Baxter Healthcare). The platelet storage container was a 1.3-litre PL 2410 plastic container (Baxter Healthcare).
S-59 Removal Device
The SRD consists of approximately 2.5 g of polystyrene beads enclosed in a polyester mesh pouch with a 1-litre PL 2410 plastic container.
Equipment
The Optipress II ® (Baxter Healthcare Corporation, Nivelles, Belgium) was used for separation of the blood collected and centrifuged van Rhenen/Vermeij/Mayaudon/Hind/Lin/ Corash in Optipac. The UVA illumination device (code No. 4R4440, Baxter Healthcare Corp., Deerfield, Ill., USA) mounted on a reciprocal platelet shaker (Helmer Labs, Noblesville, Ind., USA) was used for illumination with a wavelenght of 320-400 nm. The UVA device is air-cooled. The output of this device was approximately 15-20 mW/ cm 2 permitting delivery of 3 J/cm 2 in approximately 3-4 min.
Blood Processing
Preparation of Buffy Coats Blood units of 500 ml B 10% were collected from volunteer donors in 70 ml CPD anticoagulant solution using triple Optipac (Baxter Healthcare). Selection of donors and the blood donation procedure were based on local standard practices. The whole blood units were kept overnight (16-20 h ) at room temperature (20 B 2°C). High-speed centrifugation (4,650 g, 10 min) was applied to separate cellular components from plasma (Beckman Instr. Inc., Fullerton, Calif., USA). Buffy coats of 55 B 5 ml were separated from plasma and packed red cells using the Optipress II standard procedure.
Preparation of Study Platelet Concentrates
Preparation of Pooled Buffy Coats. Using a sterile docking device SCD312 (Terumo, Japan), a pool of 20 ABO-compatible buffy coats was made in a 1.3-litre PL 2410 plastic container. After thorough mixing, the pool was separated into equal volumes in four 600-ml transfer packs. To one container the standard volume of approximately 300 ml T-Sol was added. To each of the three remaining containers 280 ml PAS III was added to reduce the plasma concentration to 30-45% for optimal PCT performance.
Preparation of Leukofiltered Platelet Concentrates. Using a sterile docking device SCD312, a buffy coat leukodepletion set, comprised of an Autostop buffy coat filter and a 1.3-litre PL 2410 plastic container, was connected to each of the 5 buffy coat pools. Low-speed centrifugation (655 g, 5 min) was applied to the bag assembly to separate the platelet-rich plasma diluted with either T-Sol or PAS III from the red cells. After centrifugation, the platelet-rich plasma diluted with T-Sol or PAS III was expressed into the PL 2410 bag through the Autostop filter.
Preparation of Untreated Platelet Concentrates (1st and 2nd Arms). The resultant leukoreduced platelet concentrate suspended in T-Sol (1st arm) and that suspended in PAS III (2nd arm) were not treated with PCT and were used as controls. They were stored on a flat-bed shaker (50-60 cycles/min) for up to 7 days at 20-24°C. Day 0 was designated as the day of collection.
Preparation of PCT Platelet Concentrates (3rd and 4th Arms). The PCT proceeded immediately after platelet processing. The process is described in the flow chart ( fig. 1 ). Step A: Transfer of the Platelet Concentrate into the Illumination Container. Using a sterile docking device SCD312, the platelet container, the S-59 container and the illumination container were sterileconnected in series. The leukoreduced platelet concentrate in plasma/PAS III was passed through the S-59 solution into the PL 2410 illumination container. The air was expressed out of the illumination container. The illumination container containing the platelet concentrate and S-59 was then separated from the S-59 container and the platelet container by heat seal.
Step B: Illumination. Platelet mixture with added S-59 in the PL 2410 illumination container was placed in the UVA illumination device. The platelet mixture was exposed to a 3 J/cm 2 treatment with UVA with agitation (60 cycles/min).
Step C: Transfer into the SRD. After UVA illumination, the illumination container was sterile-connected to an SRD. The platelet mixture was transferred into the SRD. The air was expressed out of the SRD container. After separating the SRD from the illumination bag by heat seal, the treated platelets were stored with agitation at 20-24°C for 9 h (3rd arm), or for 16 h (4th arm) in the SRD.
Step D: Platelet Storage. After the incubation period in an SRD, the platelet mixture was transferred into a 1.3-litre PL 2410 plastic storage container for continued storage for up to 7 days from collection with agitation on a flat-bed shaker (50-60 cycles/min) at 20-24°C (day 0 is day of collection). In vitro Platelet Assays Platelet aliquots were drawn under sterile conditions on storage day 1 (before addition of S-59 for arms 3 and 4), 2, 3, 5 and 7.
Haematological parameters were measured electronically (Cell Dyn 3500, Abbott Laboratories, Chicago, Ill., USA) and leukocyte contamination was measured microscopically in a Nageotte chamber. Blood gases and bicarbonate were analysed with a 238 pH Blood Gas System (Ciba Corning, UK).
Glucose concentration and lactate concentration were measured in a Dimension Chemistry Analyzer (Dupont, Wilmington, Del., USA). ATP was measured with a chemiluminescence method in a Lumicount counter (Packard Corp., Groningen, NL).
For estimation of platelet activation, GMP140 expression (pselectin) by flow cytometry was measured by two-color labelling using a FACScan (Becton & Dickinson, San Jose, Calif., USA). FITC labelling of platelets was performed with anti-CD42. GMP expression was determined using anti-CD62 (PE). Both reagents are manufactured by Becton & Dickinson. The assay method was as follows: platelets were fixed in 1% paraformaldehyde and directly labelled with anti-CD42 (FITC) and anti-CD62 (PE); the scatter gates were set on the platelet population fraction; laser excitation was at 488 nm.
Hypotonic shock response was measured as described by Holm et al. [5] . Measurements were performed on a spectrophotometer (LKB, Ultrospect II, Cambridge, UK).
The samples for electron microscopy (EM) were prepared according to the method described by Klinger and Kluter [6] . For test platelet concentrates, samples were taken on day 1 after UVA illumination and on days 2 and 5 of storage. For control platelet concentrates, samples were taken in parallel with the test platelets on days 1, 2 and 5. Briefly, all platelet samples were embedded in Araldite resin, then polymerized in fresh resin at 60-70°C for up to 48 h. From the subsequent resin blocks produced, semi-and ultra-thin sections were cut and collected on nickel grids. These were stained using saturated alcoholic uranyl acetate and lead citrate, examined and images recorded using transmission EM. A minimum of 4 images from each sample were analyzed for platelet morphology using a final magnification of !6,500. Platelets with abnormal morphologic ultrastructure characterized by extreme swelling and loss of cytoplasmic organelles were enumerated as 'lysed platelets'. Samples were analysed blind-coded.
Lysed platelets can be distinguished from normal platelets, and are characterised by extreme swelling and pallor of the cytoplasmic contents due to the disintegration and subsequent loss of cytoplasmic proteins and organelles such as mitochondria, the open canalicular system as well as the microtubules which maintain their normal discoid shape and their pseudopods.
Statistical Analysis
In vitro data were expressed as the arithmetic mean B SD. All data from day 2 to day 7 were analysed using analysis of variance (ANOVA) to determine significant differences between the four groups of platelet concentrate treatments. The difference was considered statistically different with p ! 0.05. The analysis was performed using StatisticaV Release 5.1 for Windows (copyright Statsoft, Inc., 1984-1996). Volume of platelet concentrates before addition of 17.5 ml of S-59. 3 Volume range during UVA illumination.
Results
Platelet Product Characteristics
The unit volume, platelet yield, and plasma content of platelet concentrates prepared from pooled buffy coats using 300 ml T-Sol were determined (table 1). The platelet concentrates prepared using the same procedures but with 280 ml of PAS III had characteristics similar to platelet concentrates prepared in T-Sol. All platelet products in PAS III met the photochemical treatment target range requirements in unit volume, platelet yield and percent plasma for PCT (table 1) .
In vitro Platelet Characteristics
Following PCT, platelets were compared to untreated control platelets during 7 days of storage. The pH was stable until day 3 and fell in all groups upon further storage (table 2) . There were statistically significant differences among study groups (p ! 0.05). However, the pH was well maintained. At day 7, the pH in all groups was greater than 6.8.
The O 2 consumption increased from day 1 to day 3 (table 3) and then slowly decreased in all products. A difference was observed between the PCT products and controls (p ! 0.05). The level of pCO 2 dropped consistently during storage in the PCT products and fell to 25-26 mm Hg on day 7 (table 4). In both control groups the level of pCO 2 stabilized after day 2. The concentration of HCO An overall reduction in platelet content of approximately 15% (3rd arm) and 19% (4th arm) after 7 days was seen in the PCT products in comparison with a reduction of 5% (1st arm) and 12% (2nd arm) in the control products (p ! 0.05). This reduction was primarily due to the volume of samples withdrawn for various function analyses (table 6) . A larger volume loss was observed during PCT processing which involved transfers of platelets from the illumination container to the SRD container and then to the storage container. No difference was seen in platelet counts per liter between SRD exposures of 9 and 16 h (table 7).
The residual leukocytes after filtration ranged from !0.1 ! 10 6 /l to 0.3 ! 10 6 /l in all four study groups. No statistically significant differences were detected among study groups. These products were considered leukoreduced.
Mean platelet volume increased during storage in both the PCT and control groups. However, there were no statistically significant differences between the study groups.
Biochemical parameters showed a fall in glucose in all groups during storage but on day 7 a sufficient amount of glucose was available for metabolism (table 8) . No difference was seen between the groups on day 5. Lactate levels increased as expected in all four groups during storage (table 9). There were statistically significant differences between the T-Sol control group and the groups in PAS III at day 7 (p ! 0.05). Analysis of total ATP showed that even at day 7 sufficient ATP was available (table 10) . There were no statistically significant differences between the TSol control group and the PCT-SRD 16-hour treated group.
Activation marker GMP-140 showed an increase in the proportion of activated platelets in both the control and the PCT group during storage (table 11) with a higher percentage of activated platelets in the PCT group (p ! 0.05).
Hypotonic shock response was stable from day 1 to day 7 during storage without any difference between the groups (table 12) . Both test and control products demonstrated preservation of the swirling phenomenon on all days through day 7.
Electron Microscopic Evaluation of Platelets
For the PCT study arms, day 1 analysis was performed on platelet samples withdrawn following UVA illumination before SRD exposure. On day 2, platelet samples were withdrawn following PCT including SRD exposure. Platelet lysis increased during storage in all groups and Table 11 . Mean measurements of GMP 140 (%) in the 4 groups (n = 6, X B SD) There were no statistically significant differences between all groups.
greater levels of platelet lysis were observed in the PCT groups (table 13) compared to controls (p ! 0.05). The observed platelet lysis apparently did not result in a change in platelet counts. No platelet count (!10 9 /l) difference was seen between SRD exposures of 9 and 16 h (table 7) .
Discussion
The use of whole-blood buffy coats for platelet concentrate preparation using a balanced mixture of plasma and platelet-additive solution is an established method [7, 8] .
To prepare a platelet concentrate for an adult patient, generally 4-8 buffy coats are pooled to provide a therapeutic dose, theoretically increasing the risk of viral and bacterial contamination of the pooled platelet concentrate. Bacterial contamination in platelet concentrates has been reported in 0.1-0.5% [9] [10] [11] of concentrates. The potentially serious effects of platelet concentrates contaminated with pathogenic micro-organisms are well known.
A PCT process to inactivate both viruses and bacteria in platelet concentrates has been developed using singledonor apheresis platelet concentrates [2, 3, 12] .
For photochemical treatment, single-donor platelets were suspended in approximately 300 ml of 35% plasma and 65% of a new platelet additive solution (PAS III) and exposed to 150 ÌM of the psoralen S-59 and a 3 J/cm 2 The proportions of lysed platelets were determined by enumeration of intact and lysed platelets in electron micrographs. Blinded observers counted at least 193 platelets in each sample. All values represent the mean B SD expressed as a percent of the total platelets counted in each group. 2 All groups with n = 3 at each sampling day with the exception of the 2 untreated controls on day 1, n = 1. treatment with long wave length ultraviolet light (UVA 320-400 nm). Under these conditions, high levels of viruses, bacteria and leukocytes were inactivated [2] [3] [4] . This study assessed the application of PCT to platelets prepared from pooled buffy coats.
Preliminary studies suggested the optimal PCT conditions were plasma concentration within the critical limits of 30-45% of the total volume. These conditions also are compatible with the pooled buffy coat method of platelet preparation utilizing T-Sol, a platelet storage medium similar to PAS III. Prior to a clinical transfusion study with PCT platelet concentrates, we conducted an in vitro study to evaluate the characteristics of pooled buffy coat concentrates in plasma and PAS III subjected to PCT and 7 days of storage. These studies were also used to develop standardized procedures for production and quality control of PCT platelet concentrates.
The in vitro platelet function studies showed no evidence of metabolic deterioration of platelets after PCT and subsequent storage for up to 7 days. The pH (37°C) of PCT platelets was maintained above 6.8 throughout the 7 days of storage. PCT did not stimulate glycolysis. Similar levels of glucose remained on day 7 for the control group with PAS III and the PCT groups. Consequently, lactate levels of PCT platelets on day 7 were comparable to control platelets in PAS III. At day 7, a sufficient amount of glucose was still available for metabolism using the current preparation methods (residual plasma of 34 B 1%). No difference was detected in total ATP at day 7 among the various study groups, confirming that platelet metabolism was conserved. Although other studies have shown an effect of UVA light on cellular mitochondrial membrane potential [13] , PCT did not affect total platelet ATP content up to 7 days of storage indicating that platelet mitochondrial function was conserved. Maintenance of the ATP level correlates with platelet viability [14] . Furthermore, the hypotonic shock response analysis was consistent with preservation of platelet energy metabolism.
Due to repeated sampling for platelet analysis and several transfers between platelet containers during PCT processing, the platelet content in both PCT groups was lower compared to the control groups. The difference in platelet content may have accounted for some of the differences in pO 2 , pCO 2 , and HCO -3 between the control groups and the PCT groups. The activation marker GMP-140 (pselectin) showed a greater increase during storage in the PCT groups. However, it is not clear from the literature whether in vitro p-selectin expression correlates with in vivo viability. Shortened survival of activated platelets after transfusion has been reported in studies on platelet apheresis [15] [16] [17] . On the other hand, it was also reported that expression of the p-selectin epitope recognized by the CD62 antibody does not correlate with in vivo platelet recovery [18] . The proportion of lysed platelets, as assessed by electron microscopy, on day 5 in both photochemically treated groups was higher than that of the control arms. It is presently unknown whether there was random loss of platelets or whether older platelets were more susceptible to lysis. The higher p-selectin levels, subtle changes in respiratory activity, and a higher proportion of platelets with altered morphology may represent an effect of PCT on small numbers of older platelets [19] .
Prior studies with 5-day-old single-donor platelets have demonstrated a small decrease in post-transfusion recovery and life span, but within an acceptable range for therapeutic support of thrombocytopenic patients [20] . Recently, studies in patients have demonstrated that PCT platelets gave an adequate platelet count increment, corrected prolonged bleeding times, and the interval to the next platelet transfuison was comparable to standard platelets [21] .
The current BC-PC preparation process with a limited content of plasma (34 B 1%) allows good maintenance of in vitro platelet function. A method was developed to control the proportion of plasma in BC-PC preparations for PCT by using the volume of the residual pooled buffy coat, the haematocrit of the residual pooled buffy coat and the volume of the buffy coat PC. The production process, which requires extra hands-on time, can be organized in such a way in the blood bank that a full time availability to the patients in hospital can be maintained.
In conclusion, the results from the in vitro studies indicate that PCT is compatible with platelet concentrates prepared from pooled buffy coats for up to 7 days of storage. These PCT pooled buffy coat platelets are currently in a clinical trial to evaluate the post-transfusion platelet count increment and the haemostatic efficacy in thrombocytopenic patients.
